EHA2023 abstracts: What’s hot in AML?

Abstract

Type

Title

Presenter

S130

Oral presentation

Preliminary results of QUIWI: a double blinded, randomized clinical trial comparing standard chemotherapy plus quizartinib versus placebo in adult patients with newly diagnosed FLT3-ITD wild-type AML

Pau Montesinos

S132

Oral presentation

Updated results of VEN-A-QUI study: a phase 1-2 trial to assess the safety and efficacy of triplets for newly diagnosed unfit AML patients: azacitidine or low-dose cytarabine with venetoclax and quizartinib

Juan Miguel Bergua Burgues

S133

Oral presentation

An entirely oral regimen of oral-ATO, ATRA and ascorbic acid in risk-adapted treatment of newly-diagnosed APL resulted in excellent clinical/molecular responses with durable remission

Harry Gill

S134

Oral presentation

FLAG-IDA combined with gemtuzumab ozogamicin (GO) reduced MRD levels and improved overall survival in NPM1mut AML independent of FLT3 and MRD status, results from the AML19 trial

Nigel Russell

P491

Poster presentation

Day 14 measurable residual disease assessment predicts treatment outcomes in patients with acute myeloid leukemia treated with intensive chemotherapy - results of the PALG-AML1/2016 study

Agnieszka Wierzbowska

P494

Poster presentation

A first-in-human study of CD123 NK cell engager SAR443579 in relapsed or refractory acute myeloid leukemia, B-cell acute lymphoblastic leukemia or high risk-myelodysplasia

Anthony Selwyn Stein

P497

Poster presentation

Clinical outcomes of NPM1-mutated acute myeloid leukemia (AML) patients with measurable residual disease (MRD) relapse after achievement of a first MRD-negative remission

Madlen Jentzsch

P525

Poster presentation

Long-term outcomes of stem cell transplant in older patients with acute myeloid leukemia treated with venetoclax + HM therapies

Keith Pratz

P554

Poster presentation

Results of a randomized placebo-controlled phase 2 study of hypomethylating agents with or without eltrombopag in elderly AML patients (DELTA)

Katja Sockel

P555

Poster presentation

Olutasidenib in post-venetoclax patients with mutant IDH1 AML

Jorge Cortes

P567

Poster presentation

Phase 1b omniverse trial: safety and tolerability of oral azacitidine in combination with venetoclax for treatment of acute myeloid leukemia

Shaun Fleming

Abstract

Type

Title

Presenter

S248

Oral presentation

SIERRA trial results with a targeted radiotherapy, Iomab-B, a myeloablative conditioning with reduced intensity tolerability yields high CR, long term survival in HSCT ineligible active R/R AML

Boglarka Gyurkocza

S310

Oral presentation

Venetoclax plus azacitidine delays deterioration of health-related quality of life in patients with acute myeloid leukemia: VIALE-A long-term follow up

Keith Pratz

Abstract

Type

Title

Presenter

LB2711

Late breaking oral presentation

BMT-CTN 1506 (MORPHO): a randomized trial of the FLT3 inhibitor gilteritinib as post-transplant maintenance for FLT3-ITD AML

—

LB2713

Late breaking oral presentation

Activity, tolerability, and resistance profile of the menin inhibitor ziftomenib in adults with relapsed/refractory NPM1- mutated AML

—

S137

Oral presentation

Impact of allogeneic hematopoietic cell transplantation in first complete remission plus FLT3 inhibition with quizartinib in acute myeloid leukemia with FLT3-ITD: results from QuANTUM-First

Richard Schlenk

S138

Oral presentation

Validation of the revised 2022 European LeukemiaNet (ELN) risk stratification in adult patients with acute myeloid leukemia

Marius Bill